Ratio Therapeutics
Ratio Therapeutics is seeking a Scientist II to lead process development and manufacturing strategy for radiopharmaceuticals, utilizing the TRILLIUM and MACROPA platforms. The role involves scaling production processes, optimizing novel radiochemistry experiments, and ensuring audit-ready data integrity across multiple clinical programs.
Headquarters
Boston, Massachusetts, United States
Company Size
11-50 employees
Founded
2021
Ratio Therapeutics is a discovery-to-early-clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals for cancer patients. Its proprietary Trillium™ targeting scaffold combines pharmacokinetic modulation with advanced chelation to generate small-molecule targeting agents that selectively deliver therapeutic radioisotopes to tumors. The company advances candidates through preclinical and early clinical studies aiming to create best-in-class targeted radiotherapeutics with improved tumor targeting and safety. Ratio focuses on innovative chemistry and translational development to bring new radioligand therapies to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ratio Therapeutics.
5% above the average for this role
Scientist/Sr. Scientist , CMC Radiochemistry (on-site in SSF)
Abdera Therapeutics
Director/Head of CMC
TwoStep Therapeutics
Sr. Associate Scientist, Radiochemistry
Bristol Myers Squibb
Associate Director, CMC Development
ARTBIO
RayzeBio Scientist, Radiochemistry
Bristol Myers Squibb
Scientist - Radiochemistry
AstraZeneca